Randomized trial shows decreased methamphetamine use in adults with use disorder, indicating potential treatment benefits.
A 12‐week Phase 3 study has found that adults with moderate to severe methamphetamine use disorder who received the antidepressant mirtazapine reported a greater decrease in methamphetamine‐using days than those receiving placebo. Use of mirtazapine was not associated with any unexpected safety concerns.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: